FDA Authorizes Regeneron Monoclonal Antibodies for COVID-19
The third EUA granted to an investigational COVID-19 therapy regimen is indicated for preventing progression from mild, to severe symptoms.
St. Jude Scientists Discover Potential Treatment for COVID-19
Immunologists have discovered possible treatments for COVID-19 using existing therapies.
FDA Approves Assay to Have a Dual Claim for Both HIV Diagnosis and Viral Load Monitoring
The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.
WHO Recommends Against Remdesivir in Hospitalized Patients
This guidance comes less than 24 hours after FDA grants an EUA for its use combined with baricitinib.
MMR Vaccine Shows Potential for Protection Against COVID-19
The measles-mumps-rubella (MMR) vaccine could potentially aid in the protection against COVID-19.
Could There be Transmission of SARS-CoV-2 in Cats and Pigs to Humans?
Two recent studies conducted by Kansas State University researchers resulted in important findings related to the current COVID-19 pandemic.
Pfizer Submits COVID-19 Vaccine to FDA for Emergency Authorization
Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.
FDA Issues an EUA for Baricitinib in Combination with Remdesivir for Severe COVID-19
This EUA is for the treatment of hospitalized patients who require oxygen.
How Do the Pfizer and Moderna COVID-19 Vaccines Compare?
SKI Complex Identified as Target for Antiviral Drugs to Combat Coronaviruses
Researchers have identified the Ski complex as a promising target for antiviral drugs in the fight against coronaviruses.
Testing Positive for SARS-CoV-2 after Recovering from COVID-19
Patients testing positive for SARS-CoV-2 after recovery and negative tests are re-examined to determine if they are reinfected and/or infectious.
Lenacapavir Reaches Primary Endpoint in Study in People Living with HIV
Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.
The AstraZeneca Oxford COVID-19 Vaccine is Safe and Provokes Immune Response
Phase 2 results include a large cohort of seniors in the study.
Fecal Microbiota Transplant Outcomes and Therapy Advances
Fecal Microbiota Transplant for Recurrent vs Refractory CDI
IDSA/SHEA Guidelines Update and ID Week: Bezlotoxumab
Expanded Role of Fidaxomicin in Treatment of CDI
Treatment Recommendations from IDSA/SHEA for CDI
Risk Factors for Recurrence of Clostridioides Difficile
Frequency of CDI Recurrence and Impact on Quality of Life
Clostridioides Difficile: Exciting Developments
Antibiotic Microbial Resistance & RBX7455 for C Diff
RBX2660 for Recurrent Clostridioides Difficile
Managing Recurrent Clostridium Difficile Infections
Clostridioides Difficile Pathogenesis & Manifestation
FDA Authorizes First At-Home COVID-19 Test
For the first time, prescribed users at suspected risk of COVID-19 can receive rapid results from home.
FDA Approves Breakthrough Therapy Designation for Investigational Drug for HIV Prevention
The US Food and Drug Administration has granted breakthrough therapy designation for an investigational drug, a long-acting, injectable cabotegravir for HIV pre-exposure-prophylaxis (PrEP).
Pfizer is Planning to File an EUA with FDA for its COVID-19 Vaccine Within Days
The investigational vaccine is being reported as 95% effective.
SARS-CoV-2 Transmitted from Humans to Mink and Back to Humans
SARS-CoV-2 outbreaks on 16 different mink farms in the Netherlands have been identified showing transmission between humans and minks.
COVID-19 Vaccine Shown to be Safe and Induces an Immune Response
The data comes from a phase 1/2 trial with the CoronaVac vaccine.
